Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Extension Study to Evaluate the Long-Term Safety, Tolerability and Efficacy of Dalfampridine Extended-Release Tablets. for the Treatment of Chronic Post-Ischemic Stroke Walking Deficits .

NCT02422940 is registered in ClinicalTrials.gov with Acorda Therapeutics as lead sponsor.

NCT NCT02422940
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02422940 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Extension Study to Evaluate the Long-Term Safety, Tolerability and Efficacy of Dalfampridine Extended-Release Tablets. for the Treatment of Chronic Post-Ischemic Stroke Walking Deficits .
Lead sponsor
Acorda Therapeutics
Phase
Phase 3
Overall status
Terminated
Start date
April 30, 2015
Completion date
January 31, 2017
Enrollment
294 (actual)
Sites
66

Conditions

As the registry lists them; a condition with its own page is linked.

post-ischemic stroke